FR2448902A1 - Neurotoxine d'escherichia coli et vaccin contre la maladie de l'oedeme du porcelet la contenant - Google Patents

Neurotoxine d'escherichia coli et vaccin contre la maladie de l'oedeme du porcelet la contenant

Info

Publication number
FR2448902A1
FR2448902A1 FR8008050A FR8008050A FR2448902A1 FR 2448902 A1 FR2448902 A1 FR 2448902A1 FR 8008050 A FR8008050 A FR 8008050A FR 8008050 A FR8008050 A FR 8008050A FR 2448902 A1 FR2448902 A1 FR 2448902A1
Authority
FR
France
Prior art keywords
escherichia coli
piglet
oedemus
same
vaccine containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8008050A
Other languages
English (en)
Other versions
FR2448902B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline RIT
Original Assignee
SmithKline RIT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline RIT filed Critical SmithKline RIT
Publication of FR2448902A1 publication Critical patent/FR2448902A1/fr
Application granted granted Critical
Publication of FR2448902B1 publication Critical patent/FR2448902B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NEUROTOXINE D'ESCHERICHIA COLI AYANT UN POIDS MOLECULAIRE MOYEN DE 100000DALTONS ET OBTENUE A PARTIR DU SURNAGEANT DE CELLULES ECLATEES D'UNE CULTURE D'ESCHERICHIA COLI D'UN SEROTYPE CAPABLE DE PROVOQUER LA MALADIE DE L'OEDEME DU PORCELET. L'INVENTION A EGALEMENT POUR OBJET UN VACCIN CONTRE LA MALADIE DE L'OEDEME DU PORCELET CONTENANT CETTE TOXINE.
FR8008050A 1976-08-18 1980-04-10 Neurotoxine d'escherichia coli et vaccin contre la maladie de l'oedeme du porcelet la contenant Granted FR2448902A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71574676A 1976-08-18 1976-08-18

Publications (2)

Publication Number Publication Date
FR2448902A1 true FR2448902A1 (fr) 1980-09-12
FR2448902B1 FR2448902B1 (fr) 1983-05-20

Family

ID=24875314

Family Applications (2)

Application Number Title Priority Date Filing Date
FR7724759A Granted FR2361913A1 (fr) 1976-08-18 1977-08-11 Vaccin contre la maladie de l'oedeme du porcelet
FR8008050A Granted FR2448902A1 (fr) 1976-08-18 1980-04-10 Neurotoxine d'escherichia coli et vaccin contre la maladie de l'oedeme du porcelet la contenant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR7724759A Granted FR2361913A1 (fr) 1976-08-18 1977-08-11 Vaccin contre la maladie de l'oedeme du porcelet

Country Status (7)

Country Link
US (1) US4136181A (fr)
JP (1) JPS5324011A (fr)
BE (1) BE857794A (fr)
DE (1) DE2737060C2 (fr)
FR (2) FR2361913A1 (fr)
GB (1) GB1581776A (fr)
NL (1) NL7709085A (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH639852A5 (fr) * 1979-07-26 1983-12-15 Om Laboratoires Sa Medicament contre les maladies infectieuses des voies urinaires et digestives.
JPH0314650Y2 (fr) * 1981-04-15 1991-04-02
US4465665A (en) * 1982-03-04 1984-08-14 Smithkline-Rit Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it
US4428931A (en) 1982-03-15 1984-01-31 Merck & Co., Inc. Bacterial toxoids and gram-negative immune globulin therefrom
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125533A (en) * 1934-01-12 1938-08-02 Cutter Lab Biologicals
US3208909A (en) * 1961-05-19 1965-09-28 Puziss Milton Anaerobic process for production of a gel-adsorbed anthrax immunizing antigen
FR2227861B1 (fr) * 1973-05-04 1976-07-02 Anvar
US4002736A (en) * 1974-12-16 1977-01-11 Pankratz Duane C Porcine bacterin
US4053584A (en) * 1975-02-12 1977-10-11 Recherche Et Industrie Therapeutiques Pre-farrowing pregnant sow piglet colibacillosis vaccines and process for their administration to pregnant sows before farrowing
GB1560934A (en) * 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders

Also Published As

Publication number Publication date
GB1581776A (en) 1980-12-17
JPS6141324B2 (fr) 1986-09-13
DE2737060A1 (de) 1978-02-23
DE2737060C2 (de) 1986-07-31
FR2448902B1 (fr) 1983-05-20
NL7709085A (nl) 1978-02-21
FR2361913A1 (fr) 1978-03-17
FR2361913B1 (fr) 1983-06-24
US4136181A (en) 1979-01-23
JPS5324011A (en) 1978-03-06
BE857794A (fr) 1978-02-16

Similar Documents

Publication Publication Date Title
Schrager et al. Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection.
BG46601A3 (bg) Метод за получаване на авермектинови производни
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
FR2470794A1 (fr) Nouvelles microparticules, leur preparation et leurs applications en biologie, notamment a la culture de cellules diploides humaines
MXPA04003078A (es) Productos de gel para debajo del brazo con un componente de polimero superabsorbente.
ATE216590T1 (de) Arzneimittelformulierungen für il-12
HUP9900800A2 (hu) Szerves vegyületeket tartalmazó készítmények
BG85500A (bg) Заместени n-(1-алкил-3-хидрокси-4-пиперидинил)бензамиди
FR2448902A1 (fr) Neurotoxine d'escherichia coli et vaccin contre la maladie de l'oedeme du porcelet la contenant
ATE362481T1 (de) Lantibiotikum
UA42819C2 (uk) Ін`єкційний та інфузійний розчин, що містить енрофлокcацин
FR2361404A1 (fr) Nouvelles 7-boxyiminoacylcephalosporines, leurs procedes de preparation et leur application en therapeutique
Yagishita et al. Histopathological studies on virulence of dipeptidyl aminopeptidase IV (DPPIV) of Porphyromonas gingivalis in a mouse abscess model: use of a DPPIV-deficient mutant
ES2115424T3 (es) Derivados prolin-amidicos basicos de los antibioticos ge 2270 y similares a ge 2270.
DK58391D0 (da) Hidtil ukendte proteaser
MX9804826A (es) Composicion para criopreservacion de organos y tratamiento de infecciones virales y bacterianas.
Jennings et al. Studies on reactions to stimuli in unicellular organisms. X. The movements and reactions of pieces of ciliate infusoria
FR2356643A1 (fr) 5-0-acyl-imidazole-4-carboxamides, leur obtention et composition pharmaceutique en contenant
NO170661C (no) Anordning for behandling av yngel paa tidlige utviklingsstadier
DE60128445D1 (de) Mutiertes cyclin g1 protein
Heckels Molecular studies on the pathogenesis of gonorrhoea
FR2357610A1 (fr) Colorants nitro-amino-azoiques dispersables, leur obtention et leur application
IT1229806B (it) Cerchietto d'anima del tallone per pneumatici.
BE819319A (fr) Nouveaux derives d'acide carbonique de 2-mercapto-4,5-dichlorothioazole.
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение

Legal Events

Date Code Title Description
ST Notification of lapse